Immune Responses and Long-Term Disease Recurrence Status After Telomerase-Based Dendritic Cell Immunotherapy in Patients With Acute Myeloid Leukemia

Cancer - United States
doi 10.1002/cncr.30696
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Correlation betweenIDH2mutations and Disease Status in Acute Myeloid Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2010English

Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients After Dendritic Cell-Based Immunotherapy

Journal of Immunology
AllergyImmunology
2004English

Natural Killer Cell Immune Escape in Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Recent Developments in Immunotherapy of Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2017English

Acute Myeloid Leukemia Stem Cells and CD33-targeted Immunotherapy

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Dendritic Cell-Based Immunotherapy

Cell Research
Cell BiologyMolecular Biology
2016English

Long-Term Follow-Up of Patients With Chronic Myeloid Leukemia Having Received Autologous Stem Cell Transplantation.

Blood
BiochemistryImmunologyCell BiologyHematology
2009English

Cell-Selective Oligonucleotide STAT3 Inhibitor for Immunotherapy of Human Acute Myeloid Leukemia

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy